Cosacthen 0.25 mg/ml Solution for Injection for Dogs

None.

Special precautions for safe use in the target species:
The safety of the veterinary medicinal product has not been established in dogs
under 5 months of age or weighing less than 4.5 kg.
Safety of the veterinary medicinal product has not been established in dogs with
diabetes mellitus or hypothyroidism.
Use only according to the benefit-risk assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Tetracosactide can cause hypersensitivity in people, particularly those with existing
allergic disorders, such as asthma. People with such allergic disorders, or a known
hypersensitivity to tetracosactide, ACTH or any of the excipients, should avoid
contact with the veterinary medicinal product. If you develop clinical symptoms
following exposure, such as skin reactions, nausea, vomiting, oedema and dizziness,
or any signs of anaphylactic shock, you should seek medical advice immediately and
show the package leaflet or label to the physician.
Wash hands after use.
Tetracosactide has not been tested in reproductive or developmental toxicity studies,
but the pharmacological effects on the hypothalamic-pituitary-adrenal axis can have
adverse effects in pregnancy. Therefore, the veterinary medicinal product should not
be administered by pregnant women.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.